FibroGen’s new PhIII data set it up for quick OK, analysts say. But can it avoid a black box warning?
Less than two months out from its PDUFA date, FibroGen has rolled out a slate of Phase III data on roxadustat that analysts say all …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
